A non-cytotoxic approach to reduce ocular fibrosis following surgery in glaucoma

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1102092

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Glaucoma surgery often leads to scar formation and blindness. We have identified a novel protein (NADPH oxidase 4; Nox4) which promotes scar formation in the eye. Lack of Nox4 in a mouse models reduces scar formation. We have demonstrated that a ‘repurposed’ drug which is currently used to treat lung diseases can also block Nox4 in the eye. We aim to determine whether this drug can be used as a novel therapy for vision loss after glaucoma surgery.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2018

Funding Scheme: Project Grants

Funding Amount: $586,979.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Ophthalmology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

fibrosis | nicotinamide adenine dinucleotide phosphate (NADPH) oxidase | reactive oxygen species (ROS) | surgery | transforming growth factor beta (TGF-beta)

Related Links